Literature DB >> 7770362

The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise capacity in patients with accessory pathway-mediated supraventricular tachycardia: a treatment comparison study.

C P Lau1, Y T Tai, P W Lee.   

Abstract

This study aims to evaluate the impact of transcatheter radiofrequency ablation on quality-of-life (QOL) and exercise capacity in patients with paroxysmal supraventricular tachycardia (SVT) on stable medical therapy and the extent of symptomatic benefits of this treatment in patients with SVT of different clinical severity. A total of 55 patients with SVT on stable medications for 3 months were randomly selected for either radiofrequency ablation treatment (46 patients) or continuation of medical therapy (medical control group, 9 patients). Severity of SVT was classified based on the frequency and duration of SVT episodes, hemodynamic disturbance, and the presence of preexcited atrial fibrillation during an episode. Treadmill exercise capacity (Bruce protocol) and QOL (questionnaire study and interview) were assessed before and at 3-month intervals for 1 year after the radiofrequency procedure and at 3 months in the medical control group. Thirty-six of 46 patients were successfully ablated in one session, and a QOL measure before and at 3 months after ablation in these patients showed an improvement in total scores for "General Health Questionnaire" (20.3 +/- 6.2 vs 16.9 +/- 5.3, P < 0.01), "Somatic Symptoms Inventory" (73.0 +/- 6.0 vs 76.1 +/- 4.1, P < 0.02), and "Sickness Impact Profile" (12.6 +/- 1.7 vs 4.9 +/- 3.9, P < 0.01). This improvement in QOL was progressive and sustained over a 1-year period. Major arrhythmia limitations, such as apprehension of strenuous activities and long distance travel, were alleviated after a successful procedure. The extent of improvement in QOL was significant for patients considered to have "mild" or "severe" arrhythmia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770362     DOI: 10.1111/j.1540-8159.1995.tb02541.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  Health care utilization among adenosine-sensitive supraventricular tachycardia patients presenting to the emergency department.

Authors:  Thomas A Dewland; Adam Oesterle; John Stein; Gregory M Marcus
Journal:  J Interv Card Electrophysiol       Date:  2017-06-10       Impact factor: 1.900

2.  Patient perception of symptoms and quality of life following ablation in patients with supraventricular tachycardia.

Authors:  Kathryn A Wood; Anita L Stewart; Barbara J Drew; Melvin M Scheinman; Erika S Froëlicher
Journal:  Heart Lung       Date:  2009-09-30       Impact factor: 2.210

3.  In vitro calibration of a system for measurement of in vivo convective heat transfer coefficient in animals.

Authors:  Chanchana Tangwongsan; Louay Chachati; John G Webster; Patrick V Farrell
Journal:  Biomed Eng Online       Date:  2006-10-26       Impact factor: 2.819

4.  Impact of Radiofrequency Ablation and Antiarrhythmic Medications on the Quality of Life of Patients with Supraventricular Tachycardias: Preliminary Validation of the Greek Version of the Umea22 (U22) Questionnaire.

Authors:  Philippe-Richard Domeyer; Smaragda Ch Giannakidou; Panagiota Kyriakou; Vasiliki Katsari; Antonios P Antoniadis; Ioannis K Lagos; Nikolaos Fragakis; Agoritsa Varaklioti; Vassilios P Vassilikos
Journal:  Biomed Res Int       Date:  2018-10-09       Impact factor: 3.411

5.  Sustained high quality of life in a 5-year long term follow-up after successful ablation for supra-ventricular tachycardia. results from a large retrospective patient cohort.

Authors:  Axel Meissner; Irini Stifoudi; Peter Weismüller; Max-Olav Schrage; Petra Maagh; Martin Christ; Thomas Butz; Hans-Joachim Trappe; Gunnar Plehn
Journal:  Int J Med Sci       Date:  2009-01-11       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.